Display options
Cite
Feroldi F, Verlaan M, Knaus H, et al. High resolution combined molecular and structural optical imaging of colorectal cancer in a xenograft mouse model. Biomed Opt Express. 2018;9(12):6186-6204doi: 10.1364/BOE.9.006186.
Feroldi, F., Verlaan, M., Knaus, H., Davidoiu, V., Vugts, D. J., van Dongen, G. A. M. S., Molthoff, C. F. M., & de Boer, J. F. (2018). High resolution combined molecular and structural optical imaging of colorectal cancer in a xenograft mouse model. Biomedical optics express, 9(12), 6186-6204. https://doi.org/10.1364/BOE.9.006186
Feroldi, Fabio, et al. "High resolution combined molecular and structural optical imaging of colorectal cancer in a xenograft mouse model." Biomedical optics express vol. 9,12 (2018): 6186-6204. doi: https://doi.org/10.1364/BOE.9.006186
Feroldi F, Verlaan M, Knaus H, Davidoiu V, Vugts DJ, van Dongen GAMS, Molthoff CFM, de Boer JF. High resolution combined molecular and structural optical imaging of colorectal cancer in a xenograft mouse model. Biomed Opt Express. 2018 Nov 13;9(12):6186-6204. doi: 10.1364/BOE.9.006186. eCollection 2018 Dec 01. PMID: 31065422; PMCID: PMC6491025.
Copy Download .nbib Format: NLM
Share it on

Biomed Opt Express. 2018 Nov 13;9(12):6186-6204. doi: 10.1364/BOE.9.006186. eCollection 2018 Dec 01.

High resolution combined molecular and structural optical imaging of colorectal cancer in a xenograft mouse model.

Biomedical optics express

Fabio Feroldi, Mariska Verlaan, Helene Knaus, Valentina Davidoiu, Danielle J Vugts, Guus A M S van Dongen, Carla F M Molthoff, Johannes F de Boer

Affiliations

  1. Department of Physics and Astronomy, LaserLaB Amsterdam, VU University Amsterdam, de Boelelaan 1081, 1081HV, Amsterdam, The Netherlands.
  2. Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Radiology & Nuclear Medicine, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.

PMID: 31065422 PMCID: PMC6491025 DOI: 10.1364/BOE.9.006186

Abstract

With the emergence of immunotherapies for cancer treatment, there is a rising clinical need to visualize the tumor microenvironment (TME) non-invasively in detail, which could be crucial to predict the efficacy of therapy. Nuclear imaging techniques enable whole-body imaging but lack the required spatial resolution. Conversely, near-infrared immunofluorescence (immuno-NIRF) is able to reveal tumor cells and/or other cell subsets in the TME by targeting the expression of a specific membrane receptor with fluorescently labeled monoclonal antibodies (mAb). Optical coherence tomography (OCT) provides three-dimensional morphological imaging of tissues without exogenous contrast agents. The combination of the two allows molecular and structural contrast at a resolution of ~15 µm, allowing for the specific location of a cell-type target with immuno-NIRF as well as revealing the three-dimensional architectural context with OCT. For the first time, combined immuno-NIRF and OCT of a tumor is demonstrated

Conflict of interest statement

The authors declare that they have no conflict of interest.

References

  1. Curr Opin Chem Biol. 2003 Oct;7(5):626-34 - PubMed
  2. Appl Opt. 2004 Jan 1;43(1):113-21 - PubMed
  3. Proc Natl Acad Sci U S A. 1992 Sep 1;89(17):7973-7 - PubMed
  4. Laryngoscope. 2006 Sep;116(9):1636-41 - PubMed
  5. Cancer Res. 2007 Dec 15;67(24):11896-905 - PubMed
  6. IEEE Trans Image Process. 2001;10(2):266-77 - PubMed
  7. Opt Lett. 2008 Oct 15;33(20):2347-9 - PubMed
  8. Science. 1991 Nov 22;254(5035):1178-81 - PubMed
  9. Phys Med Biol. 2010 Jan 7;55(1):191-206 - PubMed
  10. Cancer. 1991 May 15;67(10):2529-37 - PubMed
  11. Physiol Rev. 2011 Jul;91(3):1071-121 - PubMed
  12. Nat Med. 2011 Sep 18;17(10):1315-9 - PubMed
  13. Opt Express. 2011 Oct 10;19(21):20886-903 - PubMed
  14. Nat Med. 2011 Nov 06;17(12):1680-4 - PubMed
  15. EJNMMI Res. 2011 Dec 01;1(1):31 - PubMed
  16. Opt Lett. 2012 Feb 1;37(3):362-4 - PubMed
  17. Nat Rev Cancer. 2012 Apr 05;12(5):363-8 - PubMed
  18. J Biomed Opt. 2012 Jul;17(7):070501 - PubMed
  19. Biomed Opt Express. 2012 Nov 1;3(11):2851-9 - PubMed
  20. Opt Express. 2012 Oct 22;20(22):24132-8 - PubMed
  21. Opt Lett. 2013 Feb 1;38(3):266-8 - PubMed
  22. Nat Rev Cancer. 2013 May;13(5):365-76 - PubMed
  23. Nat Protoc. 2013 May;8(5):1010-8 - PubMed
  24. Nat Rev Clin Oncol. 2013 Sep;10(9):507-18 - PubMed
  25. Opt Lett. 2013 Nov 1;38(21):4514-7 - PubMed
  26. MAbs. 2014 Jan-Feb;6(1):34-45 - PubMed
  27. Opt Express. 2013 Dec 16;21(25):30849-58 - PubMed
  28. Angew Chem Int Ed Engl. 2014 Apr 7;53(15):3796-827 - PubMed
  29. Circ Cardiovasc Interv. 2014 Aug;7(4):560-9 - PubMed
  30. Biomed Opt Express. 2014 Aug 06;5(9):2978-87 - PubMed
  31. Q J Nucl Med Mol Imaging. 2015 Mar;59(1):18-38 - PubMed
  32. Br J Surg. 2015 Jan;102(2):e56-72 - PubMed
  33. Opt Express. 2015 Feb 9;23(3):3390-402 - PubMed
  34. Int J Cancer. 2015 Oct 15;137(8):1910-20 - PubMed
  35. Clin Cancer Res. 2015 Aug 15;21(16):3658-66 - PubMed
  36. Biomed Opt Express. 2015 Mar 16;6(4):1293-303 - PubMed
  37. Biomed Opt Express. 2015 Mar 19;6(4):1363-75 - PubMed
  38. Biomed Opt Express. 2015 Apr 21;6(5):1767-81 - PubMed
  39. J Nucl Med. 2016 Mar;57(3):480-5 - PubMed
  40. J Biomed Opt. 2016 Nov 1;21(11):116008 - PubMed
  41. Cancer Res. 2017 Feb 1;77(3):623-631 - PubMed
  42. Nat Rev Clin Oncol. 2017 Jun;14(6):347-364 - PubMed
  43. Chem Soc Rev. 2017 Apr 18;46(8):2237-2271 - PubMed
  44. Lancet Gastroenterol Hepatol. 2016 Dec;1(4):283-290 - PubMed
  45. J Nucl Med. 2017 Jul;58(7):1019-1024 - PubMed
  46. Opt Lett. 2017 Oct 1;42(19):3753-3756 - PubMed
  47. Lancet Gastroenterol Hepatol. 2018 Mar;3(3):181-191 - PubMed
  48. Cancer. 1993 Jun 1;71(11):3478-85 - PubMed
  49. Cancer Res. 1994 May 15;54(10):2643-9 - PubMed

Publication Types